Efficacy and safety of bempedoic acid for prevention of cardiovascular events and diabetes: a systematic review and meta-analysis
Abstract Background Bempedoic acid is an oral, once-daily, first-in-class drug being developed for the treatment of hyperlipidemia. However, evidence of bempedoic acid use for the prevention of cardiovascular events and diabetes is lacking. Thus, we aim to evaluate the benefit and safety of bempedoi...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-08-01
|
Series: | Cardiovascular Diabetology |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12933-020-01101-9 |
id |
doaj-1dff464523aa4227af93258672d64ff3 |
---|---|
record_format |
Article |
spelling |
doaj-1dff464523aa4227af93258672d64ff32020-11-25T03:36:29ZengBMCCardiovascular Diabetology1475-28402020-08-011911910.1186/s12933-020-01101-9Efficacy and safety of bempedoic acid for prevention of cardiovascular events and diabetes: a systematic review and meta-analysisXing Wang0Yu Zhang1Huiwen Tan2Peng Wang3Xi Zha4Weelic Chong5Liangxue Zhou6Fang Fang7West China Hospital, Sichuan UniversityWest China Hospital, Sichuan UniversityWest China Hospital, Sichuan UniversityAffiliated Hospital of Chengdu University, Chengdu UniversityAffiliated Hospital of Chengdu University, Chengdu UniversitySidney Kimmel Medical College, Thomas Jefferson UniversityWest China Hospital, Sichuan UniversityWest China Hospital, Sichuan UniversityAbstract Background Bempedoic acid is an oral, once-daily, first-in-class drug being developed for the treatment of hyperlipidemia. However, evidence of bempedoic acid use for the prevention of cardiovascular events and diabetes is lacking. Thus, we aim to evaluate the benefit and safety of bempedoic acid use for the prevention of cardiovascular events and diabetes. Methods We searched Medline, Embase, and the Cochrane Central Register of Controlled Trials with no language restriction from inception until March 3, 2020. Pairs of reviewers independently identified randomized controlled trials comparing the use of bempedoic acid with placebo or no treatment for primary prevention of cardiovascular events in statin-intolerant patients with hypercholesterolemia. The primary outcomes were major adverse cardiac events, and percent change in LDL-C. Results We identified 11 trials including a total of 4391 participants. Bempedoic acid use was associated with a reduction in composite cardiovascular outcome (RR 0.75, 95% CI 0.56–0.99; I2 = 0%). Bempedoic acid reduced LDL-C levels (MD − 22.91, 95% CI − 27.35 to − 18.47; I2 = 99%), and similarly reduced CRP levels (MD -24.70, 95% CI − 32.10 to − 17.30; I2 = 53%). Bempedoic acid was associated with a reduction in rates of new-onset or worsening diabetes (RR 0.65, 95% CI 0.44–0.96; I2 = 23%). Conclusions Bempedoic acid in patients with hypercholesterolemia was associated with a lower risk of cardiovascular events and diabetes.http://link.springer.com/article/10.1186/s12933-020-01101-9Bempedoic acidPreventionCardiovascular diseaseMeta-analysis |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Xing Wang Yu Zhang Huiwen Tan Peng Wang Xi Zha Weelic Chong Liangxue Zhou Fang Fang |
spellingShingle |
Xing Wang Yu Zhang Huiwen Tan Peng Wang Xi Zha Weelic Chong Liangxue Zhou Fang Fang Efficacy and safety of bempedoic acid for prevention of cardiovascular events and diabetes: a systematic review and meta-analysis Cardiovascular Diabetology Bempedoic acid Prevention Cardiovascular disease Meta-analysis |
author_facet |
Xing Wang Yu Zhang Huiwen Tan Peng Wang Xi Zha Weelic Chong Liangxue Zhou Fang Fang |
author_sort |
Xing Wang |
title |
Efficacy and safety of bempedoic acid for prevention of cardiovascular events and diabetes: a systematic review and meta-analysis |
title_short |
Efficacy and safety of bempedoic acid for prevention of cardiovascular events and diabetes: a systematic review and meta-analysis |
title_full |
Efficacy and safety of bempedoic acid for prevention of cardiovascular events and diabetes: a systematic review and meta-analysis |
title_fullStr |
Efficacy and safety of bempedoic acid for prevention of cardiovascular events and diabetes: a systematic review and meta-analysis |
title_full_unstemmed |
Efficacy and safety of bempedoic acid for prevention of cardiovascular events and diabetes: a systematic review and meta-analysis |
title_sort |
efficacy and safety of bempedoic acid for prevention of cardiovascular events and diabetes: a systematic review and meta-analysis |
publisher |
BMC |
series |
Cardiovascular Diabetology |
issn |
1475-2840 |
publishDate |
2020-08-01 |
description |
Abstract Background Bempedoic acid is an oral, once-daily, first-in-class drug being developed for the treatment of hyperlipidemia. However, evidence of bempedoic acid use for the prevention of cardiovascular events and diabetes is lacking. Thus, we aim to evaluate the benefit and safety of bempedoic acid use for the prevention of cardiovascular events and diabetes. Methods We searched Medline, Embase, and the Cochrane Central Register of Controlled Trials with no language restriction from inception until March 3, 2020. Pairs of reviewers independently identified randomized controlled trials comparing the use of bempedoic acid with placebo or no treatment for primary prevention of cardiovascular events in statin-intolerant patients with hypercholesterolemia. The primary outcomes were major adverse cardiac events, and percent change in LDL-C. Results We identified 11 trials including a total of 4391 participants. Bempedoic acid use was associated with a reduction in composite cardiovascular outcome (RR 0.75, 95% CI 0.56–0.99; I2 = 0%). Bempedoic acid reduced LDL-C levels (MD − 22.91, 95% CI − 27.35 to − 18.47; I2 = 99%), and similarly reduced CRP levels (MD -24.70, 95% CI − 32.10 to − 17.30; I2 = 53%). Bempedoic acid was associated with a reduction in rates of new-onset or worsening diabetes (RR 0.65, 95% CI 0.44–0.96; I2 = 23%). Conclusions Bempedoic acid in patients with hypercholesterolemia was associated with a lower risk of cardiovascular events and diabetes. |
topic |
Bempedoic acid Prevention Cardiovascular disease Meta-analysis |
url |
http://link.springer.com/article/10.1186/s12933-020-01101-9 |
work_keys_str_mv |
AT xingwang efficacyandsafetyofbempedoicacidforpreventionofcardiovasculareventsanddiabetesasystematicreviewandmetaanalysis AT yuzhang efficacyandsafetyofbempedoicacidforpreventionofcardiovasculareventsanddiabetesasystematicreviewandmetaanalysis AT huiwentan efficacyandsafetyofbempedoicacidforpreventionofcardiovasculareventsanddiabetesasystematicreviewandmetaanalysis AT pengwang efficacyandsafetyofbempedoicacidforpreventionofcardiovasculareventsanddiabetesasystematicreviewandmetaanalysis AT xizha efficacyandsafetyofbempedoicacidforpreventionofcardiovasculareventsanddiabetesasystematicreviewandmetaanalysis AT weelicchong efficacyandsafetyofbempedoicacidforpreventionofcardiovasculareventsanddiabetesasystematicreviewandmetaanalysis AT liangxuezhou efficacyandsafetyofbempedoicacidforpreventionofcardiovasculareventsanddiabetesasystematicreviewandmetaanalysis AT fangfang efficacyandsafetyofbempedoicacidforpreventionofcardiovasculareventsanddiabetesasystematicreviewandmetaanalysis |
_version_ |
1724549785279528960 |